Milan, Italy

Anna Spelta

This inventor holds 1 USPTO granted patent. Top assignee: Carlo Erba. Active years: 1977.


% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 9(Granted Patents)


Company Filing History:


Years Active: 1977

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Anna Spelta

Introduction

Anna Spelta is a notable inventor based in Milan, Italy. She has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that have therapeutic applications. Her work focuses on addressing platelet aggregation disorders, which can lead to serious health issues.

Latest Patents

Anna Spelta holds a patent for "Isoindoline derivatives having platelet anti-aggregating activity." This patent describes a composition and method for the prevention and treatment of syndromes caused by platelet-aggregation disorders. The active ingredient in her invention is a compound of a specific formula, where R can be hydrogen or a C1-C4 alkyl group, and R1 can be hydrogen, a C1-C4 alkyl group, or other specified structures. This innovative approach has the potential to improve treatment options for patients suffering from related conditions. She has 1 patent to her name.

Career Highlights

Anna Spelta is currently associated with Carlo Erba, a company known for its contributions to the pharmaceutical industry. Her role at the company allows her to further her research and development efforts in the field of medicinal chemistry.

Collaborations

One of her notable collaborators is Pier Nicola Giraldi, with whom she has worked on various projects related to her patent.

Conclusion

Anna Spelta's innovative work in developing isoindoline derivatives showcases her commitment to advancing medical science. Her contributions have the potential to significantly impact the treatment of platelet aggregation disorders.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…